Author: Christensen, Bianca; Favaloro, Emmanuel J.; Lippi, Giuseppe; Van Cott, Elizabeth M.
Title: Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19) Cord-id: wdk1cszp Document date: 2020_9_2
ID: wdk1cszp
Snippet: Over the past few months, Coronavirus Disease 2019 (COVID-19) has spread across much of the world leading to a pandemic. Many infected individuals do not experience signs or symptoms, or experience only mild symptoms, whilst a subset experience severe disease, which is often fatal. A number of laboratory tests have been found to be abnormal in hospitalized patients, and some studies suggest some of these tests can predict an unfavorable outcome. These include markers of acute phase reaction (ele
Document: Over the past few months, Coronavirus Disease 2019 (COVID-19) has spread across much of the world leading to a pandemic. Many infected individuals do not experience signs or symptoms, or experience only mild symptoms, whilst a subset experience severe disease, which is often fatal. A number of laboratory tests have been found to be abnormal in hospitalized patients, and some studies suggest some of these tests can predict an unfavorable outcome. These include markers of acute phase reaction (elevated C-reactive protein, erythrocyte sedimentation rate, white blood cell count, fibrinogen, procalcitonin, factor VIII, von Willebrand factor), signs of tissue injury (elevated lactic dehydrogenase, alanine aminotransferase, cardiac troponins), changes in hemostasis and coagulation (elevated D-dimer, prolonged prothrombin time, decreased platelets, decreased antithrombin, elevated factor VIII and von Willebrand factor), and decreased lymphocytes. Additional studies are needed to confirm the most ideal panel of tests, and to confirm the efficiency of laboratory tests to predict clinical outcome, as well as the ideal anticoagulation management.
Search related documents:
Co phrase search for related documents- acro ischemia and low molecular weight: 1, 2, 3, 4
- acro ischemia and low molecular weight heparin: 1, 2, 3, 4
- activity level and acute ards respiratory distress syndrome: 1
- activity level and acute kidney injury: 1
- activity level and additional study: 1
- activity level and liver injury: 1, 2
- activity level and low molecular weight: 1
- activity level and lymphocyte count: 1, 2
- acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and admission pt: 1
- acute ards respiratory distress syndrome and admission require: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute ards respiratory distress syndrome and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- acute ards respiratory distress syndrome and lmwh low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and lmwh prophylactic dose: 1
- acute ards respiratory distress syndrome and lmwh receive: 1
- acute ards respiratory distress syndrome and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome and lupus anticoagulant: 1
Co phrase search for related documents, hyperlinks ordered by date